These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1126 related items for PubMed ID: 33882426

  • 1. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT, Arndt N, Roman C, Geremakis C, Mendoza JP, Su R, Makin C, Avila RL, Vignos MC.
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [Abstract] [Full Text] [Related]

  • 2. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
    Newsome SD, Mokliatchouk O, Castrillo-Viguera C, Naylor ML.
    Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
    [Abstract] [Full Text] [Related]

  • 3. Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.
    Moccia M, Santoni L, Vaccari I, Affinito G, Caliendo D, Rubba F, Lanzillo R, Triassi M, Brescia Morra V, Palladino R.
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):411-418. PubMed ID: 38235893
    [Abstract] [Full Text] [Related]

  • 4. Teriflunomide for multiple sclerosis.
    He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.
    Cochrane Database Syst Rev; 2016 Mar 22; 3(3):CD009882. PubMed ID: 27003123
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L, Guo S, Kinter E, Fay M.
    J Med Econ; 2016 Jul 22; 19(7):684-95. PubMed ID: 26947984
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA, Kamal KM, Pawar G.
    J Manag Care Spec Pharm; 2017 Jun 22; 23(6):666-676. PubMed ID: 28530523
    [Abstract] [Full Text] [Related]

  • 7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
    Coyle PK, Shang S, Xiao Z, Dong Q, Castrillo-Viguera C.
    Mult Scler Relat Disord; 2018 May 24; 22():134-138. PubMed ID: 29679749
    [Abstract] [Full Text] [Related]

  • 11. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A, NTD Study Group.
    J Neurol; 2018 Dec 24; 265(12):2980-2992. PubMed ID: 30327931
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R, Negroski D, Wynn D, Sellers D, Bzdek KG, Lublin AL, Rawlings AM, Quach C, Wells DP, Dumlao M, Bora A, Ranno AE, Luo KL, Chavin J, Hua LH, Becker D.
    Mult Scler Relat Disord; 2023 Feb 24; 70():104472. PubMed ID: 36566698
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF.
    J Med Econ; 2017 Mar 24; 20(3):228-238. PubMed ID: 27730845
    [Abstract] [Full Text] [Related]

  • 19. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
    Comi G, Freedman MS, Meca-Lallana JE, Vermersch P, Kim BJ, Parajeles A, Edwards KR, Gold R, Korideck H, Chavin J, Poole EM, Coyle PK.
    BMC Neurol; 2020 Oct 06; 20(1):364. PubMed ID: 33023488
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.